WEBULL

EyePoint (EYPT) Adds Retina Leadership, Is The 64% Undervaluation Case Convincing?

Simply Wall St · 2d ago

EyePoint (EYPT) stock is back in focus after the company appointed retina specialist Tarek S. Hassan, M.D., as Senior Vice President and Chief Strategic Science Officer, which ties fresh leadership directly to its late stage retinal pipeline.

See our latest analysis for EyePoint.

EyePoint’s share price is $14.72, with a 30 day share price return of 12.97% and a year to date decline of 15.79%. The 1 year total shareholder return of 44.74% and 5 year total shareholder return of 87.52% point to momentum that has been building over a longer horizon as investors weigh the late stage retinal pipeline and leadership updates such as Dr. Hassan’s appointment.

If you are tracking how specialist healthcare stories like EyePoint compare with peers using advanced therapies, it could be worth checking out 40 healthcare AI stocks.

EyePoint now has a high profile retina expert helping steer a late stage pipeline, yet the stock trades at $14.72 and the company currently reports a loss on its income line. Is that a fair price for what is on offer?

Most Popular Narrative: 63.7% Undervalued

The most followed valuation narrative puts EyePoint’s fair value at $40.54 versus the current $14.72 share price, framing a steep implied discount before factoring in execution risk.

Expansion into diabetic macular edema (DME), underpinned by positive Phase II results and a growing diabetic population worldwide, introduces significant pipeline diversification and potential for long-term revenue streams.

Read the complete narrative.

Want to see what sits behind that pipeline driven valuation gap? The core narrative leans on rapid revenue expansion, margin improvement and a rich future earnings multiple.

Result: Fair Value of $40.54 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside story around EyePoint sits alongside real pressure points, including its heavy reliance on DURAVYU and ongoing net losses while reported revenue remains small.

Find out about the key risks to this EyePoint narrative.

Next Steps

With EyePoint’s story pulling in both optimism and caution, it makes sense to move quickly and weigh the full picture for yourself using 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond EyePoint?

If you like the EyePoint story, do not stop here. Broaden your watchlist with other focused ideas that could sharpen your overall investment approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.